Aurora Cannabis Inc
TSX:ACB

Watchlist Manager
Aurora Cannabis Inc Logo
Aurora Cannabis Inc
TSX:ACB
Watchlist
Price: 6.25 CAD -0.16% Market Closed
Market Cap: 354.4m CAD

Aurora Cannabis Inc
Investor Relations

Aurora Cannabis, Inc. engages in the production, distribution and sale of cannabis products. The firm's principal business lines are focused on the production, distribution and sale of cannabis and cannabis related products in Canada and internationally. The firm's portfolio of brands includes Aurora, Aurora Drift, San Rafael '71, Daily Special, MedReleaf, CanniMed, Whistler, Reliva and KG7 CBD. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia; and Odense, Denmark. The firm is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets. The company produces approximately 150,000 kilograms (kg) of cannabis biomass annually. Its subsidiaries include 1769474 Alberta Ltd., 2105657 Alberta Inc., Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Aurora Nordic Cannabis A/S, and Reliva, LLC, among others.

Show more
Loading
ACB
S&P TSX Composite Index (Canada)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Nov 5, 2025
AI Summary
Q2 2026

Revenue Growth: Aurora’s net revenue rose 11% to $90.4 million, driven by strong gains in global medical cannabis and international markets.

Margin Expansion: Adjusted gross margin improved by 700 basis points to 61%; medical cannabis margins reached a record 69%, exceeding targets.

Profitability: Adjusted EBITDA increased 52% to $15.4 million, outpacing revenue growth.

Cash Position: Aurora ended the quarter with $142 million in cash and no cannabis business debt.

Guidance: Management expects continued year-over-year revenue growth and positive free cash flow in Q3, led by 8–12% growth in global medical cannabis.

Canada Policy Watch: Potential changes to veterans' cannabis reimbursement are under review, but management cited uncertainty on impact.

International Strength: Aurora maintained or gained share in key medical cannabis markets including Canada, Germany, Poland and the U.K.

Key Financials
Net Revenue
$90.4 million
Global Medical Cannabis Net Revenue
$70.5 million
Consumer Cannabis Net Revenue
$6.9 million
VIVO Plant Propagation Net Revenue
$11.6 million
Consolidated Adjusted Gross Margin
61%
Medical Cannabis Adjusted Gross Margin
69%
Consumer Cannabis Adjusted Gross Margin
27%
Plant Propagation Adjusted Gross Margin
10%
Adjusted EBITDA
$15.4 million
Adjusted Gross Profit
$51.8 million
Adjusted Net Income
$7.1 million
Cash and Cash Equivalents
$142 million
Free Cash Flow
-$42.3 million
Adjusted SG&A
$35.5 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Miguel Martin
CEO & Executive Chairman
No Bio Available
Ms. Simona King CPA
Chief Financial Officer
No Bio Available
Mr. Alex Miller
Executive Vice President of Operations & Supply Chain
No Bio Available
Ms. Nathalie Clark
Executive VP, General Counsel & Corporate Secretary
No Bio Available
Mr. Andre Jerome
Executive Vice President of Global Business Development
No Bio Available
Mr. Ananth Krishnan
Vice President of Capital Markets & Investor Relations
No Bio Available
Michelle Lefler
Vice President of Communications & Public Relations
No Bio Available
Ms. Lori Schick
Executive Vice President of Human Resources
No Bio Available
Dr. Jonathan Page Ph.D.
Senior Science Advisor
No Bio Available
Mr. Rick Savone
Senior Vice President of Global Government Relations
No Bio Available

Contacts

Address
ALBERTA
4818 31 Street East, Edmonton International Airport
Contacts
+16043625207.0
www.auroramj.com